CD86 and neoplasm: In the present study, we reconfirmed this idea by showing a significant increase in the proportion of CD86+ DC cells in tumor tissues after VVL-TD-mIL-27 treatment at day 6, and this phenomenon was also observed in lymph nodes and spleens.